AstriVax Therapeutics

Leuven ·KBO/BCE: BE 0787.990.881

Loading dossier…

Year closed	Due by	Filed	Variance	Reference
31-12-2025	31-07-2026	21-05-2026	71 d early	2026-00116751
31-12-2024	31-07-2025	23-07-2025	8 d early	2025-00296775
31-12-2023	31-07-2024	26-06-2024	35 d early	2024-00164562

Metric	This company	Sector median	Position in the sector
Solvency	85.3%	46.6%	better than 87% of 84 sector peers
Net result	€-7.66M	€15k	better than 5% of 83 sector peers
Equity	€10.69M	€86k	better than 95% of 84 sector peers
Total assets	€12.53M	€251k	better than 95% of 84 sector peers

Line item	Code	2025
Balance sheet, Assets
TOTAL ASSETS	20/58	€12.53M
Fixed assets	21/28	€1.27M
Intangible fixed assets	21	€600k
Tangible fixed assets	22/27	€619k
Financial fixed assets	28	€53k
Current assets	29/58	€11.26M
Stocks & contracts in progress	3	€0
Amounts receivable within one year	40/41	€938k
Investments	50/53	€5.00M
Cash & bank	54/58	€3.19M
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES	10/49	€12.53M
Equity	10/15	€10.69M
Contributions / capital	10/11	€15.77M
Accumulated profits (losses)	14	€-5.08M
Amounts payable	17/49	€1.84M
Amounts payable after one year	17	€22k
Amounts payable within one year	42/48	€956k
Trade debts payable within one year	44	€687k
Income statement
Operating result	9901	€-8.17M
Financial income	75	€171k
Financial charges	65	€23k
Result before taxes	9903	€-8.03M
Income taxes	67/77	€-369k
Net result for the period	9904	€-7.66M
Result to be appropriated	9905	€-7.66M

Summary

NACE primary	Speur- en ontwikkelingswerk op biotechnologisch gebied(72101)
Legal form	Public limited company(014)
Incorporation	04-07-2022
Status	Active
Postal code	3001